Hourglass Capital’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $7.41M | Sell |
34,070
-4,846
| -12% | -$1.07M | 1.54% | 27 |
|
|
2025
Q4 | $8.89M | Sell |
38,916
-3,960
| -9% | -$902K | 1.92% | 11 |
|
|
2025
Q3 | $9.93M | Buy |
42,876
+12,890
| +43% | +$2.62M | 2.23% | 9 |
|
|
2025
Q2 | $5.57M | Sell |
29,986
-2,902
| -9% | -$539K | 1.38% | 36 |
|
|
2025
Q1 | $6.89M | Sell |
32,888
-2,770
| -8% | -$538K | 1.8% | 18 |
|
|
2024
Q4 | $6.34M | Sell |
35,658
-13,845
| -28% | -$2.55M | 1.75% | 21 |
|
|
2024
Q3 | $9.78M | Sell |
49,503
-31,165
| -39% | -$5.82M | 2.72% | 2 |
|
|
2024
Q2 | $13.8M | Sell |
80,668
-1,960
| -2% | -$325K | 4.11% | 1 |
|
|
2024
Q1 | $15M | Sell |
82,628
-1,428
| -2% | -$246K | 4.53% | 1 |
|
|
2023
Q4 | $13M | Sell |
84,056
-520
| -0.6% | -$75.8K | 4.2% | 1 |
|
|
2023
Q3 | $12.6M | Sell |
84,576
-465
| -0.5% | -$68.3K | 4.45% | 1 |
|
|
2023
Q2 | $11.5M | Sell |
85,041
-445
| -0.5% | -$65.3K | 3.99% | 1 |
|
|
2023
Q1 | $13.6M | Sell |
85,486
-3,201
| -4% | -$489K | 4.92% | 1 |
|
|
2022
Q4 | $14.3M | Sell |
88,687
-925
| -1% | -$142K | 5.05% | 1 |
|
|
2022
Q3 | $12M | Buy |
89,612
+420
| +0.5% | +$60.3K | 4.56% | 1 |
|
|
2022
Q2 | $13.7M | Buy |
89,192
+821
| +0.9% | +$125K | 4.84% | 1 |
|
|
2022
Q1 | $14.3M | Buy |
88,371
+1,595
| +2% | +$232K | 4.48% | 1 |
|
|
2021
Q4 | $11.7M | Sell |
86,776
-20,980
| -19% | -$2.48M | 3.93% | 1 |
|
|
2021
Q3 | $11.6M | Sell |
107,756
-4,360
| -4% | -$498K | 3.16% | 4 |
|
|
2021
Q2 | $12.6M | Buy |
112,116
+945
| +0.9% | +$106K | 2.94% | 7 |
|
|
2021
Q1 | $12M | Buy |
111,171
+6,630
| +6% | +$709K | 3.04% | 4 |
|
|
2020
Q4 | $11.2M | Sell |
104,541
-4,090
| -4% | -$393K | 3.33% | 2 |
|
|
2020
Q3 | $9.52M | Buy |
108,631
+1,710
| +2% | +$161K | 3.21% | 2 |
|
|
2020
Q2 | $10.5M | Buy |
106,921
+36,076
| +51% | +$3.18M | 3.72% | 2 |
|
|
2020
Q1 | $5.4M | Buy |
70,845
+1,050
| +2% | +$89.4K | 2.29% | 11 |
|
|
2019
Q4 | $6.18M | Sell |
69,795
-2,190
| -3% | -$182K | 1.67% | 28 |
|
|
2019
Q3 | $5.45M | Buy |
71,985
+950
| +1% | +$65.1K | 1.55% | 33 |
|
|
2019
Q2 | $5.17M | Buy |
71,035
+29,173
| +70% | +$2.29M | 1.47% | 34 |
|
|
2019
Q1 | $3.37M | Sell |
41,862
-3,880
| -8% | -$317K | 0.98% | 41 |
|
|
2018
Q4 | $4.22M | Sell |
45,742
-208
| -0.5% | -$18.3K | 1.33% | 36 |
|
|
2018
Q3 | $4.35M | Buy |
45,950
+350
| +0.8% | +$33.2K | 1.13% | 41 |
|
|
2018
Q2 | $4.22M | Sell |
45,600
-4,270
| -9% | -$417K | 1.06% | 41 |
|
|
2018
Q1 | $4.72M | Sell |
49,870
-35,700
| -42% | -$3.92M | 1.08% | 40 |
|
|
2017
Q4 | $8.28M | Sell |
85,570
-1,310
| -2% | -$123K | 1.88% | 19 |
|
|
2017
Q3 | $7.72M | Sell |
86,880
-50
| -0.1% | -$3.81K | 1.84% | 19 |
|
|
2017
Q2 | $6.3M | Buy |
86,930
+650
| +0.8% | +$43.7K | 1.58% | 30 |
|
|
2017
Q1 | $5.62M | Buy |
86,280
+400
| +0.5% | +$25.1K | 1.36% | 34 |
|
|
2016
Q4 | $5.38M | Buy |
85,880
+82,050
| +2,142% | +$5.01M | 1.33% | 34 |
|
|
2016
Q3 | $242K | Hold |
3,830
| – | – | 0.06% | 91 |
|
|
2016
Q2 | $237K | Hold |
3,830
| – | – | 0.06% | 97 |
|
|
2016
Q1 | $219K | Hold |
3,830
| – | – | 0.06% | 101 |
|
|
2015
Q4 | $227K | Hold |
3,830
| – | – | 0.06% | 102 |
|
|
2015
Q3 | $208K | Hold |
3,830
| – | – | 0.05% | 103 |
|
|
2015
Q2 | $257K | Hold |
3,830
| – | – | 0.04% | 100 |
|
|
2015
Q1 | $224K | Hold |
3,830
| – | – | 0.03% | 110 |
|
|
2014
Q4 | $251K | Sell |
3,830
-2,500
| -39% | -$158K | 0.05% | 101 |
|
|
2014
Q3 | $366K | Sell |
6,330
-77,370
| -92% | -$4.3M | 0.05% | 94 |
|
|
2014
Q2 | $4.72M | Hold |
83,700
| – | – | 0.69% | 52 |
|
|
2014
Q1 | $4.3M | Sell |
83,700
-1,100
| -1% | -$55.6K | 0.72% | 56 |
|
|
2013
Q4 | $4.48M | Sell |
84,800
-4,305
| -5% | -$212K | 0.72% | 51 |
|
|
2013
Q3 | $3.99M | Buy |
89,105
+610
| +0.7% | +$27K | 0.7% | 56 |
|
|
2013
Q2 | $3.66M | Buy |
+88,495
| New | +$3.87M | 0.67% | 59 |
|
Other funds holding ABBV
VCM
VPM
Hourglass Capital's ABBV Position: Q1 2026 in Review
Hourglass Capital reduced its AbbVie (ABBV) stake by 12% in Q1 2026, selling an estimated $1.07M and leaving 34,070 shares worth $7.41M. The position accounts for 1.54% of the portfolio, ranked #27.
Hourglass Capital first reported a position in ABBV in Q2 2013 and has held it in 52 quarters since. The position peaked at $15M in Q1 2024. 4,075 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.
- Hourglass Capital held 34,070 shares of AbbVie worth $7.41M as of Q1 2026.
- Hourglass Capital sold 4,846 AbbVie shares in Q1 2026, an estimated $1.07M.
- AbbVie made up 1.54% of Hourglass Capital's portfolio in Q1 2026, its #27 holding.
- Hourglass Capital first reported a position in AbbVie in Q2 2013 and has held it in 52 quarters since.
- Hourglass Capital's AbbVie position peaked at $15M in Q1 2024.
- 4,075 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.
Based on Hourglass Capital's 13F filing for Q1 2026, filed 4 May 2026.